
Daniel T. McKillop
Partner
201-896-7115 dmckillop@sh-law.comFirm Insights
Author: Daniel T. McKillop
Date: June 28, 2016

Partner
201-896-7115 dmckillop@sh-law.comThe use, possession, sale, cultivation, and transportation of marijuana, whether for recreational or medical use, is illegal under federal law. However, over the last several years, both Congress and President Obama have signaled that well-regulated state medical marijuana programs should not be targeted for federal enforcement especially with the introduction of the Compassionate Use Medical Marijuana Act. As a result, the District of Columbia, Guam, and more than 20 states have legalized medical marijuana use.

Medical marijuana use was legalized in the Garden State in 2010 with the enactment of the New Jersey Compassionate Use Medical Marijuana Act (the “Act”). The New Jersey Department of Health implemented the Act by creating the New Jersey Medical Marijuana Program (“MMP”). The MMP authorizes approved physicians to disburse up to two ounces of medical marijuana to a registered patient during any 30-day period to treat numerous “debilitating medical conditions,” particularly where conventional treatments are ineffective or exacerbate a patient’s suffering.
These conditions include seizure disorders, including epilepsy, skeletal muscular spasticity, glaucoma, HIV, AIDS, cancer, muscular dystrophy, and inflammatory bowel disease. Patients with terminal illness may also enter the MMP where a physician provides a prognosis of fewer than 12 months of life.
Private employers in New Jersey have had a difficult time reconciling their workplace processes and policies with the intricacies of the MMP. These difficulties have often resulted in terminations of employees based on their status as MMP patients, or because they tested positive for medical marijuana. Consequently, some MMP patients have filed wrongful termination lawsuits against their former employers.
A bill currently passed before the Legislature is designed to amend the Act to address this issue. The bill serves to clarify the rights and obligations of employers, employees, and job applicants regarding hiring and termination decisions in situations involving medical marijuana use.
The bill, S2161/A2482 (the “Amendment”), proposes the following:
“The Amendment provides employers with significant legal protections.”
The Amendment provides employers with significant legal protections. Notably, the Amendment would not restrict an employer’s ability to prohibit the possession or use of “intoxicating substances” during work hours or to take related adverse employment action. Also, in recognition of the illegality of marijuana use under federal law, the Amendment specifically states that it would not require employers to commit any act that would cause the employer to be in violation of federal law, or that would result in the loss of a federal contract or federal funding.

The language of the Amendment gives rise to several questions, especially with respect to the amount of discretion granted to employers regarding current employees. For example, what “specific articulable symptoms” might employers successfully cite to terminate an employee based on medical marijuana use? What metrics would employers be required to use to demonstrate a decrease or lessening of an employee’s job performance? To what degree would an employee’s performance have to decrease to support termination? What recourse would be available to terminated employees?
It is highly likely that the Amendment will then be revised as it proceeds through the Legislature. New Jersey employers and MMP patients should act now to familiarize themselves with the Amendment and should closely monitor related developments this fall to stay apprised of their respective rights and obligations.
Disclaimer: Possession, use, distribution, and/or sale of cannabis is a Federal crime and is subject to related Federal policy. Legal advice provided by Scarinci Hollenbeck, LLC is designed to counsel clients regarding the validity, scope, meaning, and application of existing and/or proposed cannabis law. Scarinci Hollenbeck, LLC will not provide assistance in circumventing Federal or state cannabis law or policy, and advice provided by our office should not be construed as such.
No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.

On January 28, 2026, staff of the U.S. Securities and Exchange Commission’s Divisions of Corporation Finance, Investment Management, and Trading and Markets issued a joint statement clarifying how existing federal securities laws apply to tokenized securities. The SEC’s “Statement on Tokenized Securities” does not establish new law, but it does provide greater clarity on the […]
Author: Dan Brecher

Operating a business in the New Jersey and New York City metropolitan region offers incredible opportunities, but it also requires navigating a dense and highly regulated legal environment. From entity formation to regulatory compliance, seemingly minor legal oversights can expose business owners to significant risk. In our work with businesses throughout the region, our attorneys […]
Author: Dan Brecher

High-profile founder litigation is more than just a media spectacle. For startup founders, these cases underscore the legal and structural risks that can arise when rapid growth outpaces formal oversight. While launching a new company can be both an exciting and deeply rewarding endeavor, founders must be mindful that it also comes with significant risks. […]
Author: Dan Brecher

Every New Jersey company should periodically evaluate its governance framework. Strong corporate governance protects directors and officers, builds investor confidence, reduces litigation exposure, and positions a company for sustainable growth. The first quarter of the year is a great time to evaluate your corporate governance practices and perform any routine maintenance needed to keep that […]
Author: Ken Hollenbeck

Being served with a lawsuit is one of the most stressful legal events a business or individual can face. Whether the claim involves a contract dispute, an employment matter, an intellectual property issue, or another legal challenge, the actions you take in the first few days can significantly shape the outcome of your case. Acting […]
Author: Robert E. Levy

Special Purpose Acquisition Companies (SPACs) continue to gain momentum as we move through 2026. After enduring a significant contraction following the 2021 boom and the regulatory scrutiny that followed, SPAC activity rebounded sharply in 2025 and now carries forward into 2026 with real momentum. The SPAC resurgence reflects broader improvements in both market conditions and the […]
Author: Dan Brecher
No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.
Consider subscribing to our Firm Insights mailing list by clicking the button below so you can keep up to date with the firm`s latest articles covering various legal topics.
Stay informed and inspired with the latest updates, insights, and events from Scarinci Hollenbeck. Our resource library provides valuable content across a range of categories to keep you connected and ahead of the curve.
Let`s get in touch!
Sign up to get the latest from the Scarinci Hollenbeck, LLC attorneys!